Drugs / XEMPRITOLIMOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03585803 | Jun 2018 → Sep 2019 | acute radiation syndrome | Intron Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XEMPRITOLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314718 ↗ |
| Known as | KMRC011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585803 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314718 ↗ |
| Route | Intramuscular | “Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml” NCT03585803 ↗ |